Next Article in Journal
Uncovering Viral Protein-Protein Interactions and their Role in Arenavirus Life Cycle
Next Article in Special Issue
Clinical Management of Filovirus-Infected Patients
Previous Article in Journal
Cytopathogenesis of Vesicular Stomatitis Virus Is Regulated by the PSAP Motif of M Protein in a Species-Dependent Manner
Previous Article in Special Issue
Filovirus Research in Gabon and Equatorial Africa: The Experience of a Research Center in the Heart of Africa
Viruses 2012, 4(9), 1619-1650; doi:10.3390/v4091619
Review

Potential Vaccines and Post-Exposure Treatments for Filovirus Infections

1,†
, 1,†
, 1
, 2
, 1
, 1
 and 1,*
1 United States Army Medical Research Institute of Infectious Diseases, Division of Virology, 1425 Porter Street, Frederick, MD 21702, USA 2 United States Food and Drug Administration (FDA), Medical Science Countermeasures Initiative (McMi), 10903 New Hampshire Avenue, Silver Spring, MD 20901, USA These authors contributed equally to this work.
* Author to whom correspondence should be addressed.
Received: 20 July 2012 / Revised: 31 August 2012 / Accepted: 4 September 2012 / Published: 20 September 2012
(This article belongs to the Special Issue Advances in Filovirus Research 2012)
View Full-Text   |   Download PDF [446 KB, uploaded 24 September 2012]

Abstract

Viruses of the family Filoviridae represent significant health risks as emerging infectious diseases as well as potentially engineered biothreats. While many research efforts have been published offering possibilities toward the mitigation of filoviral infection, there remain no sanctioned therapeutic or vaccine strategies. Current progress in the development of filovirus therapeutics and vaccines is outlined herein with respect to their current level of testing, evaluation, and proximity toward human implementation, specifically with regard to human clinical trials, nonhuman primate studies, small animal studies, and in vitro development. Contemporary methods of supportive care and previous treatment approaches for human patients are also discussed.
Keywords: filovirus; Ebola; ebolavirus; Marburg virus; marburgvirus; vaccines; post-exposure treatments; clinical trials; non-human primates; animal models filovirus; Ebola; ebolavirus; Marburg virus; marburgvirus; vaccines; post-exposure treatments; clinical trials; non-human primates; animal models
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Share & Cite This Article

Export to BibTeX |
EndNote


MDPI and ACS Style

Friedrich, B.M.; Trefry, J.C.; Biggins, J.E.; Hensley, L.E.; Honko, A.N.; Smith, D.R.; Olinger, G.G. Potential Vaccines and Post-Exposure Treatments for Filovirus Infections. Viruses 2012, 4, 1619-1650.

View more citation formats

Related Articles

Article Metrics

Comments

Citing Articles

[Return to top]
Viruses EISSN 1999-4915 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert